Key result
Administration of atorvastatin 10 mg and 80 mg for 30 weeks did not improve endothelium-dependent vasodilatation in patients with type 2 diabetes (P>0.8).
Why the study?
Does atorvastatin 10 mg or 80 mg improve endothelial function in patients with type 2 diabetes and dyslipidemia without a history of cardiovascular disease?
RCT (n=133)
Double-blind
Randomized
Does atorvastatin 10 mg or 80 mg improve endothelial function in patients with type 2 diabetes and dyslipidemia without a history of cardiovascular disease?
Answers are grounded in this paper and cite their sources.
In patients with type 2 diabetes without prior cardiovascular disease, 30 weeks of atorvastatin therapy did not improve endothelial function despite significant lipid lowering.
OBJECTIVE: Endothelial dysfunction is considered an important early marker of atherosclerosis and cardiovascular risk and is currently used as a surrogate end point for cardiovascular risk in clinical trials. Type 2 diabetic patients show a characteristic dyslipidemia. Aggressive lipid lowering might be an effective method to improve endothelial function in these patients. RESEARCH DESIGN AND METHODS: A randomized, double-blind, placebo-controlled trial was completed to study the effect of 30 weeks' administration of atorvastatin 10 mg and 80 mg on endothelial function, as assessed by B-mode ultrasound of the brachial artery, in 133 patients with type 2 diabetes without a history of cardiovascular disease. RESULTS: Patients with diabetes and diabetic dyslipidemia had considerable endothelium-dependent and endothelium-independent dysfunction; mean flow-mediated vasodilation (SD) was 3.16% (3.56), and mean response on sublingual nitroglycerin was 6.58% (6.04). Despite substantial lowering of all atherogenic lipid parameters, no improvement of endothelium-dependent vasodilatation was found (P > 0.8). CONCLUSIONS: We observed considerable baseline endothelium-dependent and endothelium-independent dysfunction in patients with diabetes and diabetic dyslipidemia without a history of cardiovascular disease. Aggressive lipid lowering by administration of atorvastatin, resulting in substantial improvement of the lipid profile, did not reverse endothelial dysfunction.
No takes yet. Share an insight, caveat, or question.
Venrooij et al. (2002) conducted an RCT in Type 2 diabetes (n=133). Atorvastatin vs. Placebo was evaluated on Endothelium-dependent vasodilatation assessed by B-mode ultrasound of the brachial artery (p=>0.8). Administration of atorvastatin 10 mg and 80 mg for 30 weeks did not improve endothelium-dependent vasodilatation in patients with type 2 diabetes (P>0.8).
Synapse has enriched 10 related papers. Consider them for comparative context: